XML 42 R29.htm IDEA: XBRL DOCUMENT v3.25.2
Summary of Significant Accounting Policies (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Jul. 22, 2024
May 25, 2023
Jul. 30, 2022
Jun. 01, 2021
May 31, 2021
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Deferred revenue           $ 696   $ 696   $ 555
Deferred revenue recognized           400 $ 200 600 $ 700  
Remaining performance obligation           1,600   1,600    
Grant period (in years)         5 years          
Research and development arrangement with federal government, total budget         $ 9,300          
Research and development arrangement with federal government, funding for subawards         $ 5,500          
Approved funding, first year       $ 800            
Approved funding for subawards, first year       $ 400            
Approval for funding, year two     $ 2,600              
Approval for funding, subawards, year two     $ 1,600              
Approval for funding, year three   $ 3,000                
Approval for funding subawards, year three   $ 1,500                
Approval for funding, year four $ 1,700                  
Approval for funding subawards, year four $ 1,000                  
Funding received for costs incurred           0 $ 600 100 $ 1,000  
Prepaid expenses and other current assets           1,701   1,701   $ 2,352
Additional Funding Agreement Terms                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Compensation earned               3,900    
Variety of Health Care Organizations | UNITED STATES | Accounts Receivable | Customer Concentration Risk                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Accounts receivable, with the exception of due           $ 300   $ 300